Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717
- 14 April 1988
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 24 (4) , 769-775
- https://doi.org/10.1016/0277-5379(88)90313-6
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.Journal of Clinical Oncology, 1986
- The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)Cancer Chemotherapy and Pharmacology, 1985
- NL-FIT: A microcomputer program for non-linear fittingComputer Programs in Biomedicine, 1983
- PATTERNS OF CROSS-RESISTANCE TO THE ANTI-FOLATE DRUGS TRIMETREXATE, METOPRINE, HOMOFOLATE, AND CB3717 IN HUMAN LYMPHOMA AND OSTEO-SARCOMA CELLS RESISTANT TO METHOTREXATE1983
- A potent antitumour quinazoline inhibitor of thymidylate synthetase: Synthesis, biological properties and therapeutic results in micePublished by Elsevier ,1981
- Reporting results of cancer treatmentCancer, 1981